Gene · 5427
POLE2: DNA polymerase epsilon 2, accessory subunit
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. POLE2: DNA polymerase epsilon 2, accessory subunit. Genes, record 5427. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5427
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P56282 | DNA polymerase epsilon subunit 2 | 527 | 4 | Ensembl, GeneID, HGNC |
Source UniProt
Patents15
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 58452 | P56282 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4318 | P56282 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 4318 | P56282 | Espacenet |
| US 12006548 B2 | 2024-06-11 | 584 | P56282 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 64942 | P56282 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 167913 | P56282 | Espacenet |
| US 10975437 B2 | 2021-04-13 | 584 | P56282 | Espacenet |
| JP 2020062004 A | 2020-04-23 | 1080 | P56282 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 238887 | P56282 | Espacenet |
| US 10190169 B2 | 2019-01-29 | 584 | P56282 | Espacenet |
1 to 10 of 15
See all 15 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ASPACYTARABINE | CHEMBL4297599 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| CLOFARABINE | CHEMBL1750 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| CYTARABINE | CHEMBL803 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| FLUDARABINE PHOSPHATE | CHEMBL1096882 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| GEMCITABINE | CHEMBL888 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| GEMCITABINE HYDROCHLORIDE | CHEMBL1637 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| TROXACITABINE | CHEMBL359164 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
Trials4,186
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | GEMCITABINE | PHASE3 | ClinicalTrials.gov | |
| NCT07604233 | CYTARABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07603557 | FLUDARABINE PHOSPHATE | PHASE2 | ClinicalTrials.gov | |
| NCT07602140 | GEMCITABINE | PHASE2 | ClinicalTrials.gov | |
| NCT07598318 | GEMCITABINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07588360 | CYTARABINE | ClinicalTrials.gov | ||
| NCT07583888 | CYTARABINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07579195 | GEMCITABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07575191 | GEMCITABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07570849 | GEMCITABINE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 4,186
See all 4,186 trialsNIH grants373
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | POLE2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA006973 | Regional Oncology Research Center | 3 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P30CA036727 | Buffett Cancer Center Support Grant | 2 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 2 | 2025 |
| P30CA082709 | Indiana University Melvin and Bren Simon Comprehensive Cancer Center Support Grant | 2 | 2025 |
| P30DK078392 | Digestive Health Center (DHC): Bench to Bedside Research in Pediatric Digestive Disease | 2 | 2025 |
| R01ES028271 | Investigation of human DNA polymerase epsilon variants | 2 | 2025 |
| R01GM134681 | The role of DNA damage tolerance pathways in human cells | 2 | 2025 |
| R35GM127026 | Cell Signaling and Cell Decisions | 2 | 2025 |
| ZIAAI001222 | Characterization of the cellular and molecular bases of inborn errors of immunity | 2 | 2025 |
1 to 10 of 373Source NIH's project files
See all 373 nih grantsPapers543
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| POLE2 of tumor cells promotes OPN secretion based on PCLAF to drive M2 macrophage polarization in clear cell renal cell carcinoma. | Cancer Gene Ther | 2026 | 42773249 | PubTator, text mining | PubMed |
| Multi-omics identification of a programmed cell death-related signature and potential target P4HB for bladder cancer based on a 101-combination machine learning and experimental validation. | Clin Exp Med | 2026 | 41925913 | PubTator, text mining | PubMed |
| Role of POLE2/GINS1-mediated AKT/mTOR pathway in RCC autophagy, proliferation, and metastasis: evidences from bioinformatic, clinical, and experimental data. | Apoptosis | 2026 | 41893924 | PubTator, text mining | PubMed |
| Concurrent Pemetrexed With EGFR-TKI Slows the Accumulation of De Novo Mutations During In Vitro Exposure. | Anticancer Res | 2026 | 41760274 | PubTator, text mining | PubMed |
| Charting the multilevel molecular response to palbociclib in ER-positive breast cancer. | NAR Cancer | 2026 | 41710088 | PubTator, text mining | PubMed |
| Exploring the role of CCT7 in prognosis, cell cycle regulation, and immune microenvironment remodeling of lung adenocarcinoma based on multi-omics datasets and functional experiments. | Biochim Biophys Acta Gen Subj | 2026 | 41429196 | PubTator, text mining | PubMed |
| Data-Driven Discovery of a Key Regulator Cyclin A2 as a Promising Therapeutic Target in Hormone-Sensitive Cancers. | Mol Biotechnol | 2026 | 40936038 | PubTator, text mining | PubMed |
| Integrative Bioinformatics and Experimental Validation Establish CCNB1 as a Potential Biomarker for Diagnosis and Prognosis in Colorectal Cancer. | Curr Issues Mol Biol | 2025 | 41614789 | PubTator, text mining | PubMed |
| The non-catalytic DNA polymerase ε subunit is an NPF motif recognition protein. | Nat Commun | 2025 | 41390769 | PubTator, text mining | PubMed |
| Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer. | Eur J Med Chem | 2025 | 40961586 | PubTator, text mining | PubMed |
1 to 10 of 543
See all 543 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5427
GET https://conductscience.org/api/genes/v1/5427/patents